CetrorelixAcetate , 98% , 120287-85-6
Synonym(s):
Cetrotide;N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide acetic acid salt;NS-75A;SB-75
CAS NO.：120287-85-6
Empirical Formula: C70H92ClN17O14
Molecular Weight: 1431.04
MDL number: MFCD00884467
EINECS: 686-384-6
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB158.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >259°C (dec.) |
| Density | 1.42±0.1 g/cm3(Predicted) |
| storage temp. | Refrigerator |
| solubility | DMSO (Slightly, Heated), Methanol (Very Slightly) |
| form | Solid |
| pka | 9.82±0.15(Predicted) |
| color | White to Off-White |
| InChIKey | SBNPWPIBESPSIF-MHWMIDJBSA-N |
Description and Uses
Cetrorelix was launched in Germany for the treatment of female infertility. It is a decapeptidic analog of luteinizing hormone-releasing hormone (LH-RH) bearing structural modifications in the crucial positions 1, 2, 3, 6 and 10 : [Ac-D-Nal1, D-4-CI Phe-2, D-Pal3, D-Cit6, D-Alal0]-GnRH. Cetrorelix is an extremely potent and long acting gonadotrophin releasing hormone (GnRH) antagonist and thus blocks gonadotrophins and sex steroid secretion immediately after administration. Moreover, it has a low histamine-releasing potency. Cetrorelix will be the first LH-RH antagonist approved worldwide. In several Phase III clinical trials, female patients receiving Cetrorelix had a successful controlled ovulation thus avoiding a premature LH-surge. Cetrorelix could be a first-choice in-vitro fertilization (IVF) treatment without the complications of current controlled ovarian hyperstimulation protocols. Cetrorelix is currently under clinical investigation for the treatment of diverse sex hormone dependent disorders such as benign prostate hypertrophy, breast, ovarian or prostate cancers and diverse gynaecological disorders.
Cetrorelix Acetate is an gonadotropin-releasing hormone antagonist and is used to treat hormone-sensitive cancers of the prostate and breast.
